$15.33 Million in Sales Expected for Cara Therapeutics, Inc. (NASDAQ:CARA) This Quarter

Wall Street analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) to report $15.33 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Cara Therapeutics’ earnings, with the lowest sales estimate coming in at $7.50 million and the highest estimate coming in at $22.28 million. The company […]

Related Keywords

New York ,United States ,Christopher Posner ,Everence Capital Management Inc ,Securities Exchange Commission ,Zacks Investment Research ,Nasdaq ,Jpmorgan Chase Co ,Patriot Financial Group Insurance Agency ,Cara Therapeutics Inc ,Canaccord Genuity Group ,Davy Global Fund Management Ltd ,Wall Street ,Cara Therapeutics ,Get Rating ,Cara Therapeutic ,Investment Research ,Genuity Group ,Exchange Commission ,Capital Management ,Financial Group Insurance Agency ,York State Teachers Retirement System ,Global Fund Management Ltd ,Nasdaq Cara ,Cara ,Medical ,Ratings ,Consensus ,